ICU Medical, Inc. ICUI R2KR3KPHARMA

Q: What is the current share price of ICU Medical, Inc. (ICUI)?

As of 2026-09-07 16:24 PDT, ICU Medical, Inc. (ICUI) trades at $167.58 on NasdaqGS. Its 52-week range is $111.90 to $187.26.

Q: What is the market capitalisation of ICUI?

ICU Medical, Inc. (ICUI) has a market capitalisation of $4.19B on NasdaqGS.

Q: What is the P/E ratio of ICUI?

ICUI trades at a trailing price-to-earnings (P/E) ratio of 90.10. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.18.

Q: What is the return on equity (ROE) of ICUI?

ICUI has a return on equity (ROE) of 2.26%. Its return on capital employed (ROCE) is 1.21%.

Q: Is ICUI a good stock to buy?

This page provides a data-driven analysis of ICU Medical, Inc. (ICUI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Instruments & Supplies · United States

https://www.icumed.com

Company Profile ↓

$167.58

+46.83% 1Y

Mkt Cap$4.19B

P/E90.10

P/B2.18

52W High$187.26

52W Low$111.90

Book Value$84.50

EPS (TTM)$1.86

Company Overview

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 14.7% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $2.23B (-6.3% YoY); net profit $732.00K.
Trailing 12 Months Year-on-year growth — revenue -12.3%.
5-Year Trend Long-term compounding — revenue CAGR 14.7%, profit CAGR -21.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	14.73%
1 Year:	-12.30%

Compounded Profit Growth

5 Years:	-21.92%
1 Year:	-

Stock Price Performance

1 Year:	+46.83%
6 Months:	+26.95%
3 Months:	+22.67%
1 Month:	+0.73%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 74% of range

$111.90 $187.26

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)41.24 · Neutral

Price Performance

1M+0.73%

3M+22.67%

6M+26.95%

1Y+46.83%

Valuation vs Sector

P/E of 90.10 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 14.7% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading at a high P/E of 90.1.
Earnings shrank at -21.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

90.10

Industry PE

25.17

Forward P/E

17.47

PEG Ratio

0.09

Book Value

$84.50

Price to Book

2.18

P/S

2.14

EV/EBITDA

16.73

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

14.73%

Profit 5Y

-21.92%

Revenue (YoY)

-12.30%

Earnings (YoY)

Profitability & Returns

ROCE

1.21%

ROE

2.26%

ROA

1.68%

Profit Margin

2.15%

Op Margin

5.73%

Gross Margin

37.93%

EPS (Latest Qtr)

$0.76

EPS (TTM)

$1.86

Balance Sheet & Liquidity

Debt/Equity

0.64

Quick Ratio

0.95

Current Ratio

2.34

Debt

$1.34B

Total Assets

$3.97B

Current Assets

$1.21B

Working Capital

$691.69M

Ownership

Promoter Holding

1.84%

Chg in Prom Hold

-0.08%

FII / Inst Holding

116.25%

Chg in FII Hold

-0.01%

Financial Snapshot

Enterprise Value

$4.19B

Total Revenue (TTM)

$2.16B

EBITDA

$311.45M

Free Cash Flow

$387.08M

Operating Cash Flow

$167.43M

Shares Outstanding

24.99M

Gross Margin

37.93%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ICUI ICU Medical, Inc. R2KR3KPHARMA	167.58	90.10	$4.19B	0.00%	1.21%	2.26%	14.73%	-21.92%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	343.24M	-	372.03M	360.46M	327.17M	-	330.93M	312.28M	307.47M	-	328.61M	303.38M	318.57M	-	318.05M	321.68M	336.06M	543.12M	561.00M	597.86M	568.65M	549.31M	553.31M	566.65M	596.46M	589.13M	604.70M	548.87M	536.99M	530.23M	551.68M
Gross Profit	43.76M	46.27M	48.26M	49.23M	50.13M	51.27M	50.76M	88.94M	88.06M	111.60M	137.49M	149.00M	151.80M	134.59M	134.64M	135.30M	103.87M	118.55M	114.14M	121.42M	106.28M	113.92M	119.87M	112.68M	123.53M	127.79M	168.83M	167.59M	186.40M	192.04M	192.33M	183.92M	185.24M	207.43M	204.85M	210.11M	208.06M	200.88M	206.23M	235.05M
Operating Income	20.32M	24.77M	-	23.95M	22.77M	22.45M	-	-16.98M	-35.93M	-3.70M	-	4.91M	31.72M	2.25M	-	30.37M	26.27M	32.90M	-	26.06M	19.56M	25.53M	-	26.57M	34.47M	38.38M	-42.16M	-48.00K	-467.00K	9.39M	2.76M	22.85M	-10.65M	7.69M	8.24M	12.89M	10.59M	13.72M	13.58M	39.13M
Net Income	13.57M	16.27M	5.46M	18.16M	16.61M	18.81M	9.51M	55.86M	-37.06M	136.00K	49.70M	4.88M	31.05M	219.00K	-7.36M	31.00M	22.83M	26.56M	20.64M	16.83M	18.91M	24.99M	26.14M	23.73M	28.40M	31.08M	-38.07M	-7.47M	-9.81M	-9.81M	-9.93M	7.24M	-39.47M	-21.41M	-32.98M	-15.48M	35.34M	-3.40M	30.13M	19.09M
Diluted EPS	0.83	0.98	0.33	1.08	0.98	1.09	0.54	2.86	-1.87	0.01	2.33	0.23	1.44	0.01	-0.36	1.44	1.06	1.24	0.96	0.78	0.88	1.16	1.21	1.09	1.31	1.43	-1.61	-0.31	-0.55	-0.41	-0.41	0.30	-1.63	-0.88	-1.35	-0.63	1.43	-0.14	1.20	0.76
R&D Expense	3.12M	4.23M	-	3.31M	3.34M	3.65M	-	11.64M	12.97M	12.77M	-	12.59M	13.57M	13.18M	-	12.82M	11.20M	12.00M	-	10.75M	10.28M	10.13M	-	10.71M	11.38M	12.24M	23.87M	22.56M	23.11M	19.76M	22.30M	20.87M	21.84M	23.39M	21.03M	23.29M	21.87M	21.25M	21.28M	22.70M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	188.14M	204.73M	228.97M	282.96M	302.19M	316.87M	313.72M	309.26M	341.67M	379.37M	1.29B	1.40B	1.27B	1.27B	1.32B	2.28B	2.26B	2.38B	2.23B
Gross Profit	78.24M	89.82M	106.28M	128.97M	142.35M	156.51M	154.73M	151.40M	180.80M	201.40M	426.10M	570.03M	471.86M	461.50M	491.49M	697.76M	739.87M	824.78M	822.04M
Operating Income	24.65M	31.38M	35.43M	47.66M	65.22M	61.28M	51.95M	39.04M	68.56M	82.94M	-13.29M	29.76M	107.36M	98.16M	123.25M	-42.90M	22.82M	42.96M	42.83M
Net Income	-	-	-	29.92M	44.67M	41.28M	40.42M	26.34M	44.98M	63.08M	68.64M	28.79M	101.03M	86.87M	103.14M	-74.29M	-29.66M	-117.69M	732.00K
Diluted EPS	1.51	1.67	1.67	2.16	3.15	2.80	2.65	1.68	2.73	3.66	3.29	1.33	4.69	4.02	4.74	-3.11	-1.23	-4.83	0.03
R&D Expense	8.11M	4.82M	2.65M	4.68M	8.59M	10.63M	12.41M	18.33M	15.71M	12.96M	51.25M	52.87M	48.61M	42.95M	47.50M	92.98M	85.34M	88.61M	87.50M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	283.43M	309.15M	309.64M	361.11M	428.51M	499.64M	541.10M	626.83M	704.69M	1.50B	1.59B	1.69B	1.76B	-	4.52B	4.38B	4.20B	4.05B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.24B	1.22B	1.44B	1.19B
Cash & Equivalents	13.15M	7.87M	55.70M	51.25M	78.85M	99.59M	146.90M	226.02M	275.81M	336.16M	445.08M	290.07M	344.78M	268.67M	396.10M	-	208.78M	254.22M	308.57M	307.96M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	696.01M	709.36M	584.68M	615.86M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	221.72M	161.57M	182.83M	180.51M
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.43B	2.26B	2.24B	1.93B
Current Liabilities	-	-	21.96M	33.70M	25.76M	29.31M	29.12M	26.89M	28.73M	42.62M	40.54M	210.29M	249.29M	248.47M	195.49M	-	494.56M	481.84M	556.18M	498.86M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.62B	1.58B	1.53B	1.27B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.73B	1.70B	1.63B	1.33B
Total Equity	224.89M	213.90M	253.03M	263.43M	271.70M	320.58M	390.86M	464.73M	508.25M	579.87M	660.15M	1.20B	1.26B	1.38B	1.50B	-	2.09B	2.12B	1.97B	2.12B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23.99M	24.14M	24.52M	24.69M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	41.51M	30.32M	51.14M	33.09M	64.49M	66.27M	65.73M	66.34M	64.19M	89.94M	154.42M	160.22M	101.92M	222.75M	267.54M	-62.13M	166.20M	204.03M	179.85M
Investing Cash Flow	-10.30M	3.51M	-37.76M	19.63M	-45.73M	-41.37M	-13.12M	-21.75M	-11.24M	16.28M	-266.87M	-103.37M	-166.89M	-98.14M	-90.69M	-1.91B	-87.95M	-88.96M	122.23M
Financing Cash Flow	-36.96M	13.98M	-17.69M	-22.88M	2.13M	21.63M	24.39M	13.65M	15.68M	2.47M	-44.35M	8.02M	-10.91M	-40.00K	-16.87M	1.64B	-35.98M	-55.80M	-311.52M
Capital Expenditure	-23.64M	-11.35M	-16.69M	-23.17M	-15.82M	-19.16M	-18.41M	-16.60M	-12.98M	-23.36M	-74.48M	-92.72M	-97.31M	-92.00M	-68.54M	-90.31M	-83.89M	-79.37M	-88.04M
Free Cash Flow	17.87M	18.97M	34.45M	9.92M	48.66M	47.11M	47.31M	49.74M	51.21M	66.58M	79.94M	67.50M	4.61M	130.75M	199.00M	-152.44M	82.31M	124.66M	91.80M
Share Buybacks	41.00M	5.86M	20.44M	28.65M	11.96M	0	3.03M	5.84M	1.52M	17.23M	4.06M	6.25M	18.64M	12.88M	8.34M	10.88M	9.35M	11.99M	8.77M

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	41.6%	43.9%	46.4%	45.6%	47.1%	49.4%	49.3%	49.0%	52.9%	53.1%	33.0%	40.7%	37.3%	36.3%	37.3%	30.6%	32.8%	34.6%	36.8%
Operating Margin %	13.1%	15.3%	15.5%	16.8%	21.6%	19.3%	16.6%	12.6%	20.1%	21.9%	-1.0%	2.1%	8.5%	7.7%	9.4%	-1.9%	1.0%	1.8%	1.9%
Net Margin %	-	-	-	10.6%	14.8%	13.0%	12.9%	8.5%	13.2%	16.6%	5.3%	2.1%	8.0%	6.8%	7.8%	-3.3%	-1.3%	-4.9%	0.0%
ROE %	-	-	-	11.0%	13.9%	10.6%	8.7%	5.2%	7.8%	9.6%	5.7%	2.3%	7.3%	5.8%	-	-3.6%	-1.4%	-6.0%	0.0%
ROCE %	-	12.0%	12.9%	16.8%	19.7%	15.3%	11.0%	7.6%	11.7%	12.5%	-1.0%	2.2%	7.4%	6.3%	-	-1.1%	0.6%	1.2%	1.2%

Shareholding Pattern

Insiders

1.84%

Institutions

116.25%

Public Float

118.42%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	15.02%	3.75M	$657.22M
2	Jupiter Topco LLC	11.13%	2.78M	$487.06M
3	Vanguard Portfolio Management LLC	5.88%	1.47M	$257.50M
4	Fuller & Thaler Asset Management Inc.	5.19%	1.30M	$227.30M
5	Vanguard Capital Management LLC	4.49%	1.12M	$196.68M
6	Dimensional Fund Advisors LP	4.21%	1.05M	$184.46M
7	State Street Corporation	4.10%	1.02M	$179.37M
8	Schroder Investment Management Group	2.96%	739.14K	$129.42M
9	Ameriprise Financial, Inc.	2.76%	689.57K	$120.74M
10	Geode Capital Management, LLC	2.64%	660.42K	$115.64M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ICUI

Google News hu, 03 Sep 2026

ICU Medical (NASDAQ: ICUI) officer plans $819K stock sale - Stock Titan

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOd2gtZ21HNWo5aFIwd1pJQWgwTHFnalZQVUxXelBCelpWT1Q0TU9OaTNXazFVNGFtU2pTQk1CSVA4ZmxEc2hJVVdRZ3cwYlVKRHU2b2pKYlRsUnBiZzVRUUFPUlJEQXg5OGNyNkJFVml2X3UxWDcyajNaWEFmU05BVnNsQzRBSTBVRzVSNE…

Google News Sun, 14 Jun 2026

ICU Medical (ICUI) Stock Valuation Check After Recent Momentum And Discount To Estimated Fair Value - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQeDZjdVU3Ulh0dHViWVpRdk1OdnpFSlhkZjZwMTdSeUdBdVBYSWN0ZGFEZHFEaVk4UmsybW1uRklVZmtoZ19UMFhsLUZvZTVyWUlVbDZwNmFBT1N2UExGMkVnZ0pCNVFtMlZBZ3M5SGc2UDY4Qm9DYnpoUHdJeThScTVlUnY5Q05PdGdsXz…

Google News Fri, 07 Aug 2026

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know - StockStory

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQczg4YVF4Nm05UXJ3c1ZSRGlUYWVqV0NDN3lZdUdTWnVoMlhvSDhsOEVqUnpMMTdEQWFaekU1QlZHQlkxS0FFY04yY0prWEk1Y1pJNm1MYUR6bGNyMlpTQjFHX3R0aXFiRzdSVXB2bVFIam1oSmZOblhQOWV4OUlhR2hyOG9vNkV0c29rZ0…

Google News Fri, 04 Sep 2026

ICU Medical (ICUI) VP, General Counsel Virginia Sanzone Sells 4, - GuruFocus

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNc25QY0dPcVF2dXppTklpaFc0SUhnX29iQmc4YjlsTTlGc1c3cjdteFdiUTUteGhBZWp2UmQ5OU1DUGNuRm5Jam42UmxMUmVxWGlYd2ViVGxaR1A3OTB3WVBUVWJnNUw3ZmtldW5YcFhxUXBEbTBqMUpsZ3dYWDVEMmdab2l3T0thYUlMWE…

Google News hu, 23 Jul 2026

ICU Medical Announces Timing of Second Quarter 2026 Earnings Release and Conference Call | ICUI Stock News - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPbFdQQmJCTGRkNnFFTWFyWG9qbkNtT2ZwN2VxWVZKTUVIZHJibi1YazFVckJwRWhHYTdWc2U1Unp6THgxUkZ0RGVHZ0lpS0tNN3dYR0VhemxKRjVIcTFrZXJybk40MFhBWHZKU1ZkXzBqTURVS0dTZS1LTDBnOEoyQ0NXSjREOUdpZExHMU…

Google News hu, 03 Sep 2026

ICU Medical (ICUI) legal chief sells stock under preset plan - Stock Titan

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQZFdUTXhIVzJDNzNSM2JRWXoxbkNCMG5idDdQWUEweEkxWXFabG1oYU5uaExpM181V0MzMWNoalJDckRjc3dsanpVZVZkUVFNd25rZWRlYzBfUDVqTzl2bkNISHAzU1pId1l0Y0xwXzN0RkRCV0lyX0hlMG5jUlRkdklFUVUweU9pbEtkZG…

ICUI — Frequently Asked Questions

What is the current share price of ICU Medical, Inc. (ICUI)?

As of 2026-09-07 16:24 PDT, ICU Medical, Inc. (ICUI) trades at $167.58 on NasdaqGS. Its 52-week range is $111.90 to $187.26.

What is the market capitalisation of ICUI?

ICU Medical, Inc. (ICUI) has a market capitalisation of $4.19B on NasdaqGS.

What is the P/E ratio of ICUI?

ICUI trades at a trailing price-to-earnings (P/E) ratio of 90.10. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.18.

What is the return on equity (ROE) of ICUI?

ICUI has a return on equity (ROE) of 2.26%. Its return on capital employed (ROCE) is 1.21%.

Is ICUI a good stock to buy?

This page provides a data-driven analysis of ICU Medical, Inc. (ICUI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

ICU Medical, Inc. ICUI R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

ICU Medical (NASDAQ: ICUI) officer plans $819K stock sale - Stock Titan

ICU Medical (ICUI) Stock Valuation Check After Recent Momentum And Discount To Estimated Fair Value - Yahoo Finance

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know - StockStory

ICU Medical (ICUI) VP, General Counsel Virginia Sanzone Sells 4, - GuruFocus

ICU Medical Announces Timing of Second Quarter 2026 Earnings Release and Conference Call | ICUI Stock News - quiverquant.com

ICU Medical (ICUI) legal chief sells stock under preset plan - Stock Titan

ICUI — Frequently Asked Questions

What is the current share price of ICU Medical, Inc. (ICUI)?

What is the market capitalisation of ICUI?

What is the P/E ratio of ICUI?

What is the return on equity (ROE) of ICUI?

Is ICUI a good stock to buy?

Explore More